Core Points - Climb Bio, Inc. has granted an inducement equity award to a new employee as part of its 2025 Inducement Plan [1] - The inducement equity award consists of a non-statutory stock option for 120,000 shares at an exercise price of $1.27 per share, with a ten-year term and a four-year vesting schedule [2] - Climb Bio is focused on developing therapeutics for immune-mediated diseases, with a pipeline that includes budoprutug and CLYM116 [3] Summary by Category Inducement Equity Award - The inducement equity award was granted on May 19, 2025, to one new employee [2] - The stock option allows the purchase of up to 120,000 shares at an exercise price equal to the closing price on the grant date [2] - The vesting schedule includes 25% vesting on the first anniversary and the remainder vesting in 36 equal monthly installments [2] Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company [3] - The company is developing therapeutics for patients with immune-mediated diseases [3] - Key products in the pipeline include budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody [3]
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)